Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:tertiary carboxamide
go back to main search page
Accession:CHEBI:140326 term browser browse the term
Definition:A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
Synonyms:related_synonym: Formula=CNOR3;   SMILES=N(C(*)=O)(*)*;   tertiary carboxamides


show annotations for term's descendants           Sort by:
 
acalabrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crp C-reactive protein affects expression ISO acalabrutinib affects the expression of CRP protein CTD PMID:32503877 NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
JBrowse link
G Il6 interleukin 6 decreases expression ISO acalabrutinib results in decreased expression of IL6 protein CTD PMID:32503877 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
butachlor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor increases activity ISO butachlor results in increased activity of AR protein CTD PMID:20143881 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases metabolic processing ISO CYP2B6 protein results in increased metabolism of butachlor CTD PMID:11133395 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Dio1 iodothyronine deiodinase 1 decreases activity ISO butachlor results in decreased activity of DIO1 protein CTD PMID:29228274 NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity ISO butachlor results in increased activity of NR1H4 protein CTD PMID:20143881 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases activity ISO butachlor results in increased activity of NR3C1 protein CTD PMID:20143881 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Thrb thyroid hormone receptor beta affects binding ISO butachlor binds to THRB protein CTD PMID:28973306 NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
JBrowse link
camostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cckar cholecystokinin A receptor increases expression EXP camostat results in increased expression of CCKAR mRNA CTD PMID:10458643 NCBI chr14:59,610,939...59,619,786
Ensembl chr14:59,611,434...59,619,783
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA] CTD PMID:27773435 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA] CTD PMID:25766432 PMID:27773435 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO PD 0325901 inhibits the reaction [camostat results in increased expression of CCND1 protein] CTD PMID:25104499 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
increases expression
ISO PD 0325901 inhibits the reaction [camostat results in increased expression of CCND3 protein] CTD PMID:25104499 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 increases expression
multiple interactions
ISO camostat results in increased expression of CCNE1 protein
PD 0325901 inhibits the reaction [camostat results in increased expression of CCNE1 protein]
CTD PMID:25104499 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of COL1A1 mRNA] CTD PMID:25766432 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of COL3A1 mRNA] CTD PMID:25766432 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of NOX2 mRNA] CTD PMID:25766432 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
ISO PD 0325901 inhibits the reaction [camostat results in increased expression of EGR1 mRNA] CTD PMID:25104499 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO camostat results in increased expression of and results in increased secretion of FGF21 protein CTD PMID:30920846 NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO PD 0325901 inhibits the reaction [camostat results in increased expression of FOS mRNA] CTD PMID:25104499 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Ier3 immediate early response 3 increases expression ISO camostat results in increased expression of IER3 mRNA CTD PMID:25104499 NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
increases phosphorylation
ISO camostat results in increased expression of JUN mRNA
camostat results in increased phosphorylation of JUN protein
CTD PMID:25104499 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression ISO camostat results in increased expression of JUNB mRNA CTD PMID:25104499 NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO PD 0325901 inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein] CTD PMID:25104499 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions
ISO camostat results in increased phosphorylation of MAPK3 protein
PD 0325901 inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]
CTD PMID:25104499 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mki67 marker of proliferation Ki-67 increases expression
multiple interactions
ISO camostat results in increased expression of MKI67 protein
PD 0325901 inhibits the reaction [camostat results in increased expression of MKI67 protein]
CTD PMID:25104499 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Nos3 nitric oxide synthase 3 increases expression EXP camostat results in increased expression of NOS3 mRNA CTD PMID:10458643 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of NOX1 mRNA] CTD PMID:25766432 NCBI chr  X:104,909,328...104,932,508
Ensembl chr  X:104,909,326...104,932,508
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
increases expression
ISO PD 0325901 inhibits the reaction [camostat results in increased expression of PCNA protein] CTD PMID:25104499 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Plg plasminogen decreases activity
multiple interactions
EXP camostat results in decreased activity of PLG protein modified form
camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
CTD PMID:27773435 NCBI chr 1:48,521,828...48,563,895
Ensembl chr 1:48,521,772...48,563,776
JBrowse link
G Rps6 ribosomal protein S6 increases phosphorylation ISO camostat results in increased phosphorylation of RPS6 protein CTD PMID:25104499 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of SERPINE1 mRNA] CTD PMID:25766432 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Smad2 SMAD family member 2 multiple interactions ISO camostat inhibits the reaction [Bleomycin results in increased phosphorylation of SMAD2 protein] CTD PMID:26599507 NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation ISO camostat results in increased phosphorylation of STAT3 protein CTD PMID:25104499 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO
EXP
camostat inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]
camostat inhibits the reaction [Adenine results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]
CTD PMID:25766432 PMID:26599507 PMID:27773435 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tmprss2 transmembrane serine protease 2 decreases activity ISO camostat results in decreased activity of TMPRSS2 protein CTD PMID:24027332 NCBI chr11:38,063,914...38,103,406
Ensembl chr11:38,063,915...38,103,290
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
camostat inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
CTD PMID:20023007 PMID:27773435 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
carfentanil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases metabolic processing ISO CYP2C8 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases metabolic processing ISO CYP3A5 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Oprm1 opioid receptor, mu 1 multiple interactions ISO Capsaicin inhibits the reaction [carfentanil binds to OPRM1 protein]; Cocaine affects the reaction [carfentanil binds to OPRM1 protein] CTD PMID:12406535 PMID:15953495 NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
JBrowse link
crotamiton term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO crotamiton results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
dimethomorph term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Anxa10 annexin A10 increases expression ISO dimethomorph results in increased expression of ANXA10 mRNA CTD PMID:32194361 NCBI chr16:29,674,699...29,741,521
Ensembl chr16:29,674,793...29,741,465
JBrowse link
G Ar androgen receptor multiple interactions ISO dimethomorph inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; dimethomorph inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] CTD PMID:21310686 PMID:33049310 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Arg1 arginase 1 decreases expression ISO dimethomorph results in decreased expression of ARG1 mRNA CTD PMID:32194361 NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 decreases expression ISO dimethomorph results in decreased expression of CYP2C19 protein CTD PMID:32194361 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression ISO dimethomorph results in decreased expression of CYP7A1 mRNA; dimethomorph results in decreased expression of CYP7A1 protein CTD PMID:32194361 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO dimethomorph binds to and results in increased activity of ESR1 protein CTD PMID:33049310 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO dimethomorph results in decreased expression of G6PC1 mRNA CTD PMID:32194361 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO dimethomorph binds to and results in increased activity of NR1I2 protein CTD PMID:33049310 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Pde4a phosphodiesterase 4A decreases activity ISO dimethomorph results in decreased activity of PDE4A protein CTD PMID:21251949 NCBI chr 8:22,189,533...22,234,036
Ensembl chr 8:22,189,600...22,233,748
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO dimethomorph binds to and results in increased activity of PPARG protein CTD PMID:33049310 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
erastin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atg5 autophagy related 5 increases expression EXP erastin results in increased expression of ATG5 protein CTD PMID:32937103 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions
increases expression
ISO GW 506033X inhibits the reaction [erastin results in increased expression of CHAC1 mRNA] CTD PMID:30817950 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO erastin affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol] CTD PMID:33017621 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO GW 506033X inhibits the reaction [erastin results in increased expression of DDIT3 mRNA] CTD PMID:30817950 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
increases phosphorylation
ISO GW 506033X inhibits the reaction [erastin results in increased phosphorylation of ERN1 protein] CTD PMID:30817950 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Fancd2 FA complementation group D2 decreases expression EXP erastin results in decreased expression of FANCD2 protein CTD PMID:32937103 NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
JBrowse link
G Fh fumarate hydratase decreases response to substance ISO FH protein results in decreased susceptibility to erastin CTD PMID:29917289 NCBI chr13:93,651,486...93,677,371
Ensembl chr13:93,651,484...93,677,377
JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions
increases expression
EXP 3-methyladenine promotes the reaction [erastin results in increased expression of FTH1 protein]; Chloroquine promotes the reaction [erastin results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein] CTD PMID:32937103 NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
EXP NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein] CTD PMID:32937103 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions
EXP erastin results in increased expression of GCLM protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]
CTD PMID:32937103 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions
ISO
EXP
erastin results in decreased expression of GPX4 protein
SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein]
CTD PMID:31323261 PMID:32937103 NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO erastin results in increased expression of HMOX1 protein CTD PMID:30817950 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hras HRas proto-oncogene, GTPase increases response to substance ISO HRAS protein modified form results in increased susceptibility to erastin CTD PMID:17568748 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 decreases phosphorylation EXP erastin results in decreased phosphorylation of HSPB1 protein CTD PMID:32937103 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions
EXP erastin results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [erastin results in increased expression of MAP1LC3B protein modified form]
CTD PMID:32937103 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
ISO erastin results in increased phosphorylation of MAPK1 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK1 protein]
CTD PMID:30817950 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK3 protein] CTD PMID:30817950 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions
ISO erastin results in increased phosphorylation of MAPK8 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK8 protein]
CTD PMID:30817950 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Ncoa4 nuclear receptor coactivator 4 decreases expression
multiple interactions
EXP erastin results in decreased expression of NCOA4 protein
3-methyladenine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]; Chloroquine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]
CTD PMID:32937103 NCBI chr16:8,302,950...8,323,294
Ensembl chr16:8,302,950...8,323,293
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
increases expression
ISO
EXP
NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of NFE2L2 protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]
CTD PMID:31323261 PMID:32937103 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP
ISO
erastin results in increased expression of PTGS2 mRNA
Vitamin E inhibits the reaction [erastin analog results in increased expression of PTGS2 mRNA]
erastin analog results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 mRNA
CTD PMID:24439385 PMID:32937103 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Sesn1 sestrin 1 multiple interactions ISO SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein] CTD PMID:31323261 NCBI chr20:46,667,116...46,758,306
Ensembl chr20:46,667,121...46,758,305
JBrowse link
G Sesn2 sestrin 2 multiple interactions
increases expression
ISO NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
Acetylcysteine inhibits the reaction [erastin results in increased expression of SESN2 protein]; Butylated Hydroxyanisole inhibits the reaction [erastin results in increased expression of SESN2 protein]; Dactinomycin inhibits the reaction [erastin results in increased expression of SESN2 mRNA]; Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein]; diphenyleneiodonium inhibits the reaction [erastin results in increased expression of SESN2 protein]; ferrostatin-1 inhibits the reaction [erastin results in increased expression of SESN2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of SESN2 mRNA; erastin results in increased expression of SESN2 protein
CTD PMID:31323261 NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
JBrowse link
G Slc11a2 solute carrier family 11 member 2 increases expression EXP erastin results in increased expression of SLC11A2 protein CTD PMID:32937103 NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
JBrowse link
G Slc40a1 solute carrier family 40 member 1 decreases expression
increases expression
EXP
ISO
erastin results in decreased expression of SLC40A1 protein
erastin results in increased expression of SLC40A1 protein
CTD PMID:31323261 PMID:32937103 NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression
multiple interactions
EXP erastin results in increased expression of SLC7A11 mRNA
NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]
CTD PMID:32937103 NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
JBrowse link
G Tf transferrin increases expression EXP erastin results in increased expression of TF protein CTD PMID:32937103 NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
JBrowse link
G Tfrc transferrin receptor increases expression EXP
ISO
erastin results in increased expression of TFRC protein CTD PMID:31323261 PMID:32937103 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Vdac2 voltage-dependent anion channel 2 decreases expression
affects binding
increases degradation
ISO
EXP
erastin results in decreased expression of VDAC2 protein
erastin analog binds to VDAC2 protein
erastin results in increased degradation of VDAC2 protein
CTD PMID:17568748 PMID:32937103 NCBI chr15:2,634,622...2,648,548
Ensembl chr15:2,634,624...2,648,551
JBrowse link
G Vdac3 voltage-dependent anion channel 3 increases degradation
decreases expression
affects response to substance
EXP
ISO
erastin results in increased degradation of VDAC3 protein
erastin results in decreased expression of VDAC3 protein
VDAC3 protein affects the susceptibility to erastin
CTD PMID:17568748 PMID:32937103 NCBI chr16:74,292,466...74,308,910
Ensembl chr16:74,292,438...74,308,903
JBrowse link
GSK2656157 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf4 activating transcription factor 4 multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein] CTD PMID:30602124 PMID:32578922 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
CTD PMID:30602124 PMID:32357311 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Ostn osteocrin multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA] CTD PMID:30602124 NCBI chr11:76,851,923...76,888,140
Ensembl chr11:76,851,322...76,888,178
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] CTD PMID:32357311 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
ibrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin affects binding ISO ibrutinib binds to ALB protein CTD PMID:26675335 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO ibrutinib results in decreased expression of BCL2L1 mRNA CTD PMID:26254443 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions ISO ibrutinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:26254443 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO ibrutinib results in decreased expression of BIRC3 mRNA CTD PMID:26254443 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger decreases expression ISO ibrutinib results in decreased expression of BMI1 mRNA CTD PMID:26254443 NCBI chr17:85,360,439...85,370,283
Ensembl chr17:85,364,483...85,368,208
JBrowse link
G Btk Bruton tyrosine kinase decreases response to substance
decreases activity
decreases phosphorylation
multiple interactions
affects binding
ISO BTK gene mutant form results in decreased susceptibility to ibrutinib; BTK protein mutant form results in decreased susceptibility to ibrutinib
ibrutinib results in decreased activity of BTK protein
ibrutinib results in decreased phosphorylation of BTK protein
(+)-JQ1 compound promotes the reaction [ibrutinib results in decreased phosphorylation of and results in decreased expression of BTK protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of and results in decreased expression of BTK protein]; ibrutinib results in decreased phosphorylation of and results in decreased expression of BTK protein
ibrutinib binds to BTK protein
CTD PMID:23296407 PMID:23425038 PMID:25189416 PMID:26174628 PMID:26254443 PMID:26675335 NCBI chr  X:105,360,922...105,390,580
Ensembl chr  X:105,360,922...105,390,580
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression ISO ibrutinib results in decreased expression of CFLAR mRNA CTD PMID:26254443 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Crebbp CREB binding protein decreases response to substance ISO CREBBP protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO ibrutinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Hbb hemoglobin subunit beta affects binding ISO ibrutinib binds to HBB protein CTD PMID:26675335 NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
decreases activity
ISO (+)-JQ1 compound promotes the reaction [ibrutinib results in decreased activity of IKBKB protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased activity of IKBKB protein] CTD PMID:25049379 NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO ibrutinib promotes the reaction [CPI203 results in decreased expression of IL10 mRNA]
ibrutinib results in decreased expression of IL10 mRNA
CTD PMID:25049379 PMID:26254443 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il6 interleukin 6 multiple interactions ISO ibrutinib promotes the reaction [CPI203 results in decreased expression of IL6 mRNA] CTD PMID:25049379 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 decreases response to substance ISO MAP3K14 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr10:91,303,428...91,353,601
Ensembl chr10:91,303,428...91,353,601
JBrowse link
G Nfkbia NFKB inhibitor alpha decreases expression ISO ibrutinib results in decreased expression of NFKBIA mRNA CTD PMID:26254443 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase decreases response to substance ISO PIM1 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
JBrowse link
G Plcg2 phospholipase C, gamma 2 multiple interactions
decreases response to substance
decreases phosphorylation
ISO (+)-JQ1 compound promotes the reaction [ibrutinib results in decreased phosphorylation of PLCG2 protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of PLCG2 protein]
PLCG2 protein mutant form results in decreased susceptibility to ibrutinib
CTD PMID:26254443 PMID:27542411 NCBI chr19:50,039,410...50,173,543
Ensembl chr19:50,045,020...50,173,220
JBrowse link
G Prdm1 PR/SET domain 1 decreases expression ISO ibrutinib results in decreased expression of PRDM1 mRNA CTD PMID:26254443 NCBI chr20:49,464,921...49,556,623
Ensembl chr20:49,464,919...49,556,518
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects localization ISO ibrutinib affects the localization of RELA protein CTD PMID:26254443 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Tnf tumor necrosis factor decreases expression ISO ibrutinib results in decreased expression of TNF mRNA CTD PMID:26254443 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 decreases expression ISO ibrutinib results in decreased expression of TNFAIP3 mRNA CTD PMID:26254443 NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
JBrowse link
G Traf2 Tnf receptor-associated factor 2 decreases response to substance ISO TRAF2 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr 3:2,746,061...2,770,690
Ensembl chr 3:2,746,075...2,770,620
JBrowse link
G Traf3 Tnf receptor-associated factor 3 decreases response to substance ISO TRAF3 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr 6:135,610,698...135,720,247
Ensembl chr 6:135,610,743...135,718,564
JBrowse link
mefenacet term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO Dihydrotestosterone inhibits the reaction [mefenacet results in increased activity of AR protein] CTD PMID:15064155 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO CYP2B6 protein results in increased metabolism of and results in decreased susceptibility to mefenacet CTD PMID:15853388 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO mefenacet binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
PHA-665752 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein] CTD PMID:22040890 PMID:25002221 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein CTD PMID:20661229 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein
Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
CTD PMID:20661229 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein] CTD PMID:22040890 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Egfr epidermal growth factor receptor decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
CTD PMID:21266357 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] CTD PMID:20661229 PMID:21812414 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
increases mutagenesis
decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
CTD PMID:20661229 PMID:21106725 PMID:21266357 PMID:21812414 PMID:25002221 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
CTD PMID:21266357 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
increases response to substance
increases expression
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
CTD PMID:21266357 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein CTD PMID:20661229 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
piperine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression
ISO Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]
piperine results in increased expression of ABCB1 mRNA; piperine results in increased expression of ABCB1 protein
CTD PMID:23707768 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] CTD PMID:25087745 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein] CTD PMID:25655587 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alb albumin multiple interactions EXP piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]] CTD PMID:17429802 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Atf2 activating transcription factor 2 decreases localization ISO piperine results in decreased localization of ATF2 protein CTD PMID:15531295 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions
ISO piperine results in increased expression of BAX protein
piperine inhibits the reaction [Curcumin results in decreased expression of BAX protein]
CTD PMID:28341137 PMID:30935902 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO piperine results in decreased expression of BCL2 protein
[piperine co-treated with Curcumin] results in decreased expression of BCL2 protein
CTD PMID:28341137 PMID:30935902 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
ISO piperine inhibits the reaction [Cadmium results in increased activity of CASP3 protein]
piperine inhibits the reaction [Curcumin results in decreased expression of CASP3 protein]
piperine results in increased cleavage of CASP3 protein
CTD PMID:16780805 PMID:28341137 PMID:30935902 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 increases cleavage ISO piperine results in increased cleavage of CASP9 protein CTD PMID:28341137 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions
decreases expression
EXP
ISO
piperine inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]
piperine results in decreased expression of CAT protein
CTD PMID:25087745 PMID:28341137 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein] CTD PMID:25655587 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO piperine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] CTD PMID:30935902 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein] CTD PMID:25655587 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein] CTD PMID:25655587 NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein] CTD PMID:25655587 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein] CTD PMID:25655587 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein] CTD PMID:25655587 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of CDKN1A protein CTD PMID:30935902 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases localization ISO piperine results in decreased localization of CREB1 protein CTD PMID:15531295 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Csf2 colony stimulating factor 2 decreases secretion
decreases expression
ISO piperine results in decreased secretion of CSF2 protein
piperine results in decreased expression of CSF2 mRNA
CTD PMID:15531295 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of CTNNB1 protein CTD PMID:30935902 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO piperine affects the localization of CYCS protein CTD PMID:28341137 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO piperine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:17012224 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 affects binding ISO piperine binds to FGFR1 protein CTD PMID:28341137 NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases localization
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of FOS protein]
piperine results in decreased localization of FOS protein
CTD PMID:15531295 PMID:21354279 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]] CTD PMID:17429802 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] CTD PMID:25087745 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO
EXP
[Curcumin co-treated with piperine] results in increased expression of HMOX1 mRNA; [Curcumin co-treated with piperine] results in increased expression of HMOX1 protein; Acetylcysteine inhibits the reaction [[Curcumin co-treated with piperine] results in increased expression of HMOX1 protein]
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein]
CTD PMID:12806184 PMID:23942037 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]; tin protoporphyrin IX inhibits the reaction [[Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]] CTD PMID:23942037 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igf1r insulin-like growth factor 1 receptor affects binding ISO piperine binds to IGF1R protein CTD PMID:28341137 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Il1b interleukin 1 beta decreases expression
decreases secretion
ISO piperine results in decreased expression of IL1B mRNA
piperine results in decreased secretion of IL1B protein
CTD PMID:15531295 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:25655587 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il6 interleukin 6 decreases secretion
decreases expression
ISO piperine results in decreased secretion of IL6 protein
piperine results in decreased expression of IL6 mRNA
CTD PMID:15531295 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein] CTD PMID:21354279 PMID:22542552 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] CTD PMID:25087745 NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
JBrowse link
G Lep leptin multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in increased expression of LEP protein] CTD PMID:25087745 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] CTD PMID:25087745 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Maoa monoamine oxidase A multiple interactions
decreases activity
ISO
EXP
[resveratrol co-treated with piperine] results in decreased activity of MAOA protein
piperine results in decreased activity of MAOA protein
CTD PMID:15120460 PMID:23943324 NCBI chr  X:6,554,698...6,620,722
Ensembl chr  X:6,554,698...6,620,722
JBrowse link
G Maob monoamine oxidase B decreases activity EXP piperine results in decreased activity of MAOB protein CTD PMID:15120460 NCBI chr  X:6,430,694...6,533,520
Ensembl chr  X:6,430,594...6,533,534
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
CTD PMID:21354279 PMID:22542552 PMID:25655587 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
CTD PMID:21354279 PMID:22542552 PMID:25655587 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase affects binding ISO piperine binds to MET protein CTD PMID:28341137 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 protein] CTD PMID:21354279 NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression ISO piperine results in decreased expression of MMP2 protein CTD PMID:15531295 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]
piperine results in decreased expression of MMP9 protein
CTD PMID:15531295 PMID:21354279 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein] CTD PMID:23707768 NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases localization ISO piperine results in decreased localization of NFKB1 protein CTD PMID:15531295 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
CTD PMID:21354279 PMID:22542552 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases expression
increases activity
affects binding
ISO [piperine co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]
piperine results in increased expression of NR1I2 protein
piperine results in increased activity of NR1I2 protein
piperine binds to NR1I2 protein
CTD PMID:23707768 PMID:25455453 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of PRKCA protein] CTD PMID:21354279 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] CTD PMID:22542552 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rel REL proto-oncogene, NF-kB subunit decreases localization ISO piperine results in decreased localization of REL protein CTD PMID:15531295 NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases localization
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of RELA protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of RELA protein]
piperine results in decreased localization of RELA protein
CTD PMID:15531295 PMID:21354279 PMID:22542552 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Slc9a3 solute carrier family 9 member A3 multiple interactions EXP [piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein] CTD PMID:12806184 NCBI chr 1:31,731,652...31,777,144
Ensembl chr 1:31,734,327...31,777,070
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein] CTD PMID:25655587 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stat5a signal transducer and activator of transcription 5A multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein] CTD PMID:25655587 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:25655587 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
G Tac1 tachykinin, precursor 1 decreases expression EXP piperine results in decreased expression of TAC1 protein CTD PMID:6205719 NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
JBrowse link
G Tgfbr1 transforming growth factor, beta receptor 1 affects binding ISO piperine binds to TGFBR1 protein CTD PMID:28341137 NCBI chr 5:63,056,071...63,119,635
Ensembl chr 5:63,050,758...63,119,635
JBrowse link
G Tnf tumor necrosis factor decreases expression
decreases secretion
ISO piperine results in decreased expression of TNF mRNA
piperine results in decreased secretion of TNF protein
CTD PMID:15531295 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of TP53 protein CTD PMID:30935902 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ugdh UDP-glucose 6-dehydrogenase decreases expression ISO piperine results in decreased expression of UGDH mRNA CTD PMID:16292757 NCBI chr14:44,479,614...44,502,845
Ensembl chr14:44,479,614...44,502,845
JBrowse link
G Utrn utrophin increases expression ISO piperine results in increased expression of UTRN mRNA CTD PMID:22028826 NCBI chr 1:6,451,809...6,970,040
Ensembl chr 1:6,451,810...6,970,040
JBrowse link
quinaprilat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO quinaprilat inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr15:106,800,081...106,844,668
Ensembl chr15:106,800,081...106,844,426
JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions ISO
EXP
quinaprilat inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr11:66,932,664...66,961,708
Ensembl chr11:66,932,614...66,961,713
JBrowse link
SCH772984 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:31706003 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Adm adrenomedullin decreases secretion
multiple interactions
EXP SCH772984 results in decreased secretion of ADM protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein]
CTD PMID:28087833 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G App amyloid beta precursor protein multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] CTD PMID:28087833 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of and results in increased expression of CREB1 protein]; SCH772984 results in decreased phosphorylation of and results in decreased expression of CREB1 protein CTD PMID:28087833 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] CTD PMID:28087833 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein] CTD PMID:31585129 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases secretion
EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
SCH772984 results in increased secretion of FGF2 protein
CTD PMID:28087833 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]] CTD PMID:28087833 PMID:32319158 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gpr4 G protein-coupled receptor 4 multiple interactions ISO SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein] CTD PMID:33161135 NCBI chr 1:80,125,639...80,136,786
Ensembl chr 1:80,135,391...80,136,880
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] CTD PMID:28087833 NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
JBrowse link
G Il6 interleukin 6 multiple interactions EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of IL6 protein] CTD PMID:28087833 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein] CTD PMID:28087833 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K1 protein CTD PMID:28087833 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K2 protein CTD PMID:28087833 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
decreases expression
decreases activity
EXP
ISO
SCH772984 results in increased phosphorylation of MAPK1 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]
SCH772984 results in decreased expression of MAPK1 protein
SCH772984 results in decreased activity of MAPK1 protein
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases activity
decreases expression
multiple interactions
increases phosphorylation
EXP
ISO
SCH772984 results in decreased activity of MAPK3 protein
SCH772984 results in decreased expression of MAPK3 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SCH772984 results in increased phosphorylation of MAPK3 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 decreases expression
multiple interactions
EXP SCH772984 results in decreased expression of MAPK8 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK8 protein]
CTD PMID:28087833 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein] CTD PMID:28087833 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of and results in increased phosphorylation of SP1 protein]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of SP1 mRNA] CTD PMID:31585129 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Spi1 Spi-1 proto-oncogene multiple interactions ISO SCH772984 inhibits the reaction [saikosaponin D results in increased expression of SPI1 protein] CTD PMID:32822868 NCBI chr 3:79,918,127...79,937,708
Ensembl chr 3:79,918,969...79,938,301
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Vim vimentin multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
spirapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ren renin increases expression
multiple interactions
EXP spirapril results in increased expression of REN mRNA; spirapril results in increased expression of REN protein
spirapril promotes the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein]
CTD PMID:1764812 PMID:9300315 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO spirapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr15:106,800,081...106,844,668
Ensembl chr15:106,800,081...106,844,426
JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions ISO
EXP
spirapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr11:66,932,664...66,961,708
Ensembl chr11:66,932,614...66,961,713
JBrowse link
trandolapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity EXP trandolapril results in decreased activity of ACE protein CTD PMID:27428043 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Ace2 angiotensin I converting enzyme 2 multiple interactions ISO trandolapril promotes the reaction [REN2 protein results in increased expression of ACE2 protein] CTD PMID:27428043 NCBI chr  X:32,050,734...32,095,860
Ensembl chr  X:32,049,931...32,096,016
JBrowse link
G Ache acetylcholinesterase multiple interactions EXP trandolapril inhibits the reaction [3-nitropropionic acid results in increased activity of ACHE protein] CTD PMID:25445565 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Adrb1 adrenoceptor beta 1 increases expression EXP trandolapril results in increased expression of ADRB1 protein CTD PMID:7586371 NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
JBrowse link
G Agt angiotensinogen multiple interactions
decreases expression
EXP
ISO
trandolapril inhibits the reaction [Isoproterenol results in increased expression of AGT protein]
trandolapril results in decreased expression of AGT protein modified form
trandolapril inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]
CTD PMID:1534315 PMID:27428043 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Cat catalase multiple interactions EXP trandolapril inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein] CTD PMID:25445565 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
decreases expression
EXP [trandolapril co-treated with eplerenone] results in decreased expression of CYBA mRNA
trandolapril results in decreased expression of CYBA mRNA
CTD PMID:17324946 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Fn1 fibronectin 1 multiple interactions EXP [trandolapril co-treated with eplerenone] results in decreased expression of FN1 protein CTD PMID:17324946 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions
decreases expression
EXP [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 mRNA; [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 protein
trandolapril results in decreased expression of NCF1 mRNA; trandolapril results in decreased expression of NCF1 protein
CTD PMID:17324946 NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
JBrowse link
G Ren renin multiple interactions
increases expression
ISO
EXP
[Bumetanide co-treated with trandolapril] results in increased expression of REN protein
trandolapril results in increased expression of REN protein
CTD PMID:16635047 PMID:27428043 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO trandolapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr15:106,800,081...106,844,668
Ensembl chr15:106,800,081...106,844,426
JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions EXP trandolapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr11:66,932,664...66,961,708
Ensembl chr11:66,932,614...66,961,713
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP trandolapril results in increased expression of SOD2 protein CTD PMID:17324946 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
ximelagatran term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G F2 coagulation factor II decreases cleavage
multiple interactions
ISO ximelagatran results in decreased cleavage of F2 protein
ximelagatran binds to and results in decreased activity of F2 protein
CTD PMID:15155122 PMID:16084352 PMID:16194202 PMID:17314111 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19786
    chemical entity 19786
      atom 19784
        nonmetal atom 19666
          nitrogen atom 18655
            nitrogen molecular entity 18655
              organonitrogen compound 18407
                carboxamide 17248
                  tertiary carboxamide 181
                    (2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid 0
                    (2R,3R,3aS,9bS)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-1-[cyclohexyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                    (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                    (2S,3S,3aR,9bR)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone 0
                    (E)-dimethomorph + 10
                    (E)-flumorph + 0
                    (Z)-dimethomorph + 10
                    (Z)-flumorph + 0
                    1-(4-\{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl\}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone + 0
                    1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one 0
                    1-methyl-1-[1-oxo-1-(10H-phenothiazin-10-yl)propan-2-yl]pyrrolidinium + 0
                    1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester 0
                    2,2-dichloro-1-[5-(furan-2-yl)-2,2-dimethyl-1,3-oxazolidin-3-yl]ethanone + 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(ethanesulfonyl)amino]-5-fluoro-4-[4-methyl-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]benzene-1-carbothioamide + 0
                    2-\{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy\}-N-(2-fluorophenyl)-N-methylpropanamide + 0
                    2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester 0
                    2-chloro-N-(2,6-dimethylphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide + 0
                    3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                    4-(dichloroacetyl)piperazine-1-carbaldehyde 0
                    4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 0
                    AZD1979 oxetane hydrolysis product 0
                    Adenocarpine 0
                    Allidochlor 0
                    Astrophylline 0
                    Casimiroedine 0
                    Dichlormid 0
                    Ethyl 3-(N-butylacetamido)propionate 0
                    GSK1016790A 0
                    GSK2656157 4
                    HMMF 0
                    LSM-14399 0
                    LSM-17487 0
                    LSM-17508 0
                    LSM-17532 0
                    LSM-17538 0
                    LSM-17628 0
                    LSM-17680 0
                    LSM-17740 0
                    LSM-25340 0
                    LSM-25384 0
                    LSM-25403 0
                    LSM-25515 0
                    LSM-25525 0
                    LSM-25537 0
                    LSM-25565 0
                    LSM-25598 0
                    LSM-9991 0
                    MK-8353 0
                    ML-210 0
                    ML162 0
                    N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                    N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                    N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                    N-(p-octylbenzoyl)-piperidin-4-ol 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(Z)-11-methyldodec-2-enoyl]piperidine 0
                    N-[(Z)-dodec-2-enoyl]morpholine 0
                    N-[(Z)-dodec-2-enoyl]piperidine 0
                    N-[(Z)-dodec-2-enoyl]pyrrolidine 0
                    N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                    N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                    N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                    N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                    N-isovalerylsarcosine 0
                    N1,N5,N10-Tricaffeoyl spermidine 0
                    OSMI-1 0
                    PF-07321332 0
                    PHA-533533 0
                    PHA-665752 12
                    R-29148 0
                    RSL3 0
                    SCH772984 24
                    SIS3 free base 0
                    acalabrutinib 2
                    althiomycin 0
                    butachlor 6
                    camostat 29
                    carfentanil 3
                    celacinnine 0
                    crotamiton 1
                    cyproflanilide 0
                    dalfopristin 0
                    delgocitinib 0
                    diloxanide furoate 0
                    erastin 30
                    ibrutinib 23
                    ivosidenib 0
                    lofentanyl 0
                    mefenacet 3
                    methylprednisolone 21-suleptanic acid ester 0
                    narlaprevir 0
                    nigerazine A 0
                    nigerazine B 0
                    nigragillin 0
                    onalespib 0
                    orthosulfamuron 0
                    piperine 63
                    pipobroman 0
                    pristinamycin IIA + 0
                    promysalin 0
                    pyrimorph 0
                    quinapril 0
                    quinaprilat 2
                    somocystinamide A 0
                    spirapril 3
                    spiraprilat + 3
                    trandolapril 13
                    trandolaprilat 0
                    tyclopyrazoflor 0
                    ximelagatran 1
                    ximelagatran (hydroxylamine form) 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19786
    subatomic particle 19784
      composite particle 19784
        hadron 19784
          baryon 19784
            nucleon 19784
              atomic nucleus 19784
                atom 19784
                  main group element atom 19675
                    p-block element atom 19675
                      carbon group element atom 19596
                        carbon atom 19586
                          organic molecular entity 19586
                            organic group 18631
                              organic divalent group 18622
                                organodiyl group 18622
                                  carbonyl group 18537
                                    carbonyl compound 18537
                                      carboxylic acid 18215
                                        carboacyl group 17441
                                          univalent carboacyl group 17441
                                            carbamoyl group 17248
                                              carboxamide 17248
                                                tertiary carboxamide 181
                                                  (2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid 0
                                                  (2R,3R,3aS,9bS)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-1-[cyclohexyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                                                  (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                                                  (2S,3S,3aR,9bR)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone 0
                                                  (E)-dimethomorph + 10
                                                  (E)-flumorph + 0
                                                  (Z)-dimethomorph + 10
                                                  (Z)-flumorph + 0
                                                  1-(4-\{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl\}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone + 0
                                                  1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one 0
                                                  1-methyl-1-[1-oxo-1-(10H-phenothiazin-10-yl)propan-2-yl]pyrrolidinium + 0
                                                  1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester 0
                                                  2,2-dichloro-1-[5-(furan-2-yl)-2,2-dimethyl-1,3-oxazolidin-3-yl]ethanone + 0
                                                  2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(ethanesulfonyl)amino]-5-fluoro-4-[4-methyl-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]benzene-1-carbothioamide + 0
                                                  2-\{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy\}-N-(2-fluorophenyl)-N-methylpropanamide + 0
                                                  2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester 0
                                                  2-chloro-N-(2,6-dimethylphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide + 0
                                                  3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                                                  4-(dichloroacetyl)piperazine-1-carbaldehyde 0
                                                  4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 0
                                                  AZD1979 oxetane hydrolysis product 0
                                                  Adenocarpine 0
                                                  Allidochlor 0
                                                  Astrophylline 0
                                                  Casimiroedine 0
                                                  Dichlormid 0
                                                  Ethyl 3-(N-butylacetamido)propionate 0
                                                  GSK1016790A 0
                                                  GSK2656157 4
                                                  HMMF 0
                                                  LSM-14399 0
                                                  LSM-17487 0
                                                  LSM-17508 0
                                                  LSM-17532 0
                                                  LSM-17538 0
                                                  LSM-17628 0
                                                  LSM-17680 0
                                                  LSM-17740 0
                                                  LSM-25340 0
                                                  LSM-25384 0
                                                  LSM-25403 0
                                                  LSM-25515 0
                                                  LSM-25525 0
                                                  LSM-25537 0
                                                  LSM-25565 0
                                                  LSM-25598 0
                                                  LSM-9991 0
                                                  MK-8353 0
                                                  ML-210 0
                                                  ML162 0
                                                  N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                                                  N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                                                  N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                                                  N-(p-octylbenzoyl)-piperidin-4-ol 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(Z)-11-methyldodec-2-enoyl]piperidine 0
                                                  N-[(Z)-dodec-2-enoyl]morpholine 0
                                                  N-[(Z)-dodec-2-enoyl]piperidine 0
                                                  N-[(Z)-dodec-2-enoyl]pyrrolidine 0
                                                  N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                                                  N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                                                  N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                                                  N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                                                  N-isovalerylsarcosine 0
                                                  N1,N5,N10-Tricaffeoyl spermidine 0
                                                  OSMI-1 0
                                                  PF-07321332 0
                                                  PHA-533533 0
                                                  PHA-665752 12
                                                  R-29148 0
                                                  RSL3 0
                                                  SCH772984 24
                                                  SIS3 free base 0
                                                  acalabrutinib 2
                                                  althiomycin 0
                                                  butachlor 6
                                                  camostat 29
                                                  carfentanil 3
                                                  celacinnine 0
                                                  crotamiton 1
                                                  cyproflanilide 0
                                                  dalfopristin 0
                                                  delgocitinib 0
                                                  diloxanide furoate 0
                                                  erastin 30
                                                  ibrutinib 23
                                                  ivosidenib 0
                                                  lofentanyl 0
                                                  mefenacet 3
                                                  methylprednisolone 21-suleptanic acid ester 0
                                                  narlaprevir 0
                                                  nigerazine A 0
                                                  nigerazine B 0
                                                  nigragillin 0
                                                  onalespib 0
                                                  orthosulfamuron 0
                                                  piperine 63
                                                  pipobroman 0
                                                  pristinamycin IIA + 0
                                                  promysalin 0
                                                  pyrimorph 0
                                                  quinapril 0
                                                  quinaprilat 2
                                                  somocystinamide A 0
                                                  spirapril 3
                                                  spiraprilat + 3
                                                  trandolapril 13
                                                  trandolaprilat 0
                                                  tyclopyrazoflor 0
                                                  ximelagatran 1
                                                  ximelagatran (hydroxylamine form) 0
paths to the root